SPECIAL NOTICE
68 -- rPA Anthrax Vaccine Advance Development
- Notice Date
- 12/29/2009
- Notice Type
- Special Notice
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, Office of the Secretary, Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, 330 Independence Avenue, SW, Rm G640, Washington, District of Columbia, 20201, United States
- ZIP Code
- 20201
- Solicitation Number
- HHSO100200900103C
- Archive Date
- 1/28/2010
- Point of Contact
- Jake Lewis, Phone: 202-205-3624, Darrick A Early, Phone: 202-260-0293
- E-Mail Address
-
jake.lewis@hhs.gov, darrick.early@hhs.gov
(jake.lewis@hhs.gov, darrick.early@hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Pursuant to Federal Acquisition Regulations (FAR) 5.201(b) (1) (ii), the Department of Health and Human Services, Assistant Secretary for Preparedness and Response, Biomedical Advance Research and Development Authority (BARDA) intends to negotiate a contract modification with PharmAthene Inc. These activities exemplify the developmental, regulatory, and project management /Earned Value Management activities relevant for the expansion of the current development effort under BARDA contract (103C). These expansion areas include: Manufacturing activities such as process scale up and validation, assay validation, and non-clinical safety assessment and study plans. PharmAthene Inc. has been under contract with the US government since 2003 to develop an rPA vaccine via Contract N01-AI-30052. These development activities were transferred to BARDA as of 4/1/2009 (HHSO100200900103C). This product has matured as demonstrated by successful clinical and non clinical studies. Many of the (R&D) activities that are currently being executed have a direct impact on the government’s urgent need to devise effective measures to protect US citizens from harmful effects of anthrax spores used as instruments of terror. In addition, they impact the Contractor’s ability to successfully execute further development. Enabling the continued work will also maintain a properly balanced sources of suppliers for the requirements of acquisition program in the interest of rPA vaccine development to achieve industrial mobilization in case of an emergency. This contract increase level of effort does not represent a material difference between the modified contract and the contract that was originally awarded. The original contract adequately advised offerors of this type requirement found in the modification. This Notice of Intent is NOT a request for competitive proposals and a solicitation will not be issued. Parties may express their interest, to the Contracting Officer no later than 4 pm, Eastern Standard Time on January 13, 2010. Interested parties should submit no more than 3 pages explaining how they can meet this government’s requirement Response may be sent to: Primary Point of Contact: Jake L. Lewis, Contracting Officer Representative Jake.lewis@hhs.gov Secondary Point of Contact: Darrick Early, Contracting Officer Darrick.Early@hhs.gov
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/OOS/OASPHEP/HHSO100200900103C/listing.html)
- Place of Performance
- Address: US Department of Health and Human Services, Assistant Secretary for Preparedness and Response, Biomedical Advance Research and Development Authority, 330 Independence Avenue, SW, Room G640, Washington, District of Columbia, 20201, United States
- Zip Code: 20201
- Zip Code: 20201
- Record
- SN02032034-W 20091231/091229233922-84ccfb33ed5f43af62a1b47d4f35fa5d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |